Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...
pharmaphorum21h
Gilead’s Trodelvy woes rise with failed bladder cancer trial
Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...
pharmaphorum21h
MHRA unveils big shakeup in UK clinical trials regs
The UK has traditionally been a stronghold for clinical research, but pressure on the NHS and a slower-than-expected recovery after the pandemic have raised red flags about the long-term health of ...